3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
16
Genitourinary
1
Conditions
Carcinoma, Renal Cell
6
Kidney Neoplasms
4
Melanoma
1
Interventions
pembrolizumab
75
Nivolumab
46
Cyclophosphamide
25
aldesleukin
23
fludarabine
16
atezolizumab
15
Ipilimumab
15
Interleukin-2
14
Radiosurgery
13
Paclitaxel
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Carboplatin
11
fludarabine phosphate
9
Docetaxel
9
durvalumab
8
Cisplatin
8
cemiplimab
7
Bevacizumab
7
Radiotherapy
6
Gemcitabine
6
Biopsy
6
spartalizumab
5
avelumab
5
Pemetrexed
5
Oxaliplatin
5
Immune Checkpoint Inhibitors
5
Filgrastim
5
Cryosurgery
5
Blood Specimen Collection
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Melanoma
×
peginterferon alfa-2b
×
Genitourinary
×
Clear all
NCT02089685
2022-09-13
MK-3475-029
Merck Sharp & Dohme LLC
Phase 1/2
Completed
295 enrolled
25 charts